v3.26.1
Restatement of Previously Issued Financial Statements - Schedule of Restated Audited Consolidated Statement of Cash Flows (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2024
Mar. 31, 2025
Jun. 30, 2025
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2023
Restated Audited Consolidated Statement of Cash Flows [Line Items]            
Consolidated net loss $ (29,565) [1] $ (30,137) [1] $ (31,827) [1] $ (49,182) $ (1,368)  
Depreciation and amortization 281 505 941 1,387 98  
Adjustment Fair Value Of Warrants       34,172 (5,185)  
Gain on standby equity purchase agreement         (2,402)  
Issuance costs related to warrants       189 371  
Issuance costs related to SEPA         319  
Amortization of notes payable discount       120  
Inventory (188) (73) (3) (96) (207)  
Accounts receivable   227 [1]   (422) 4,218  
Non-operating losses          
Deferred income taxes       (108) 626  
Change in operating lease liabilities       221 190  
Accrued expenses and other payable   (88) [1]   1,280 (82)  
Net cash used in operating activities (2,358) [1] (4,937) [1] (5,409) [1] (8,911) (4,941)  
Purchase of PPE (138) (386) (4,839) (5,144) (844)  
Purchase of intangible assets     (84) [1] (590) (5,471)  
Purchase of short-term investments       (50,028) (15,940)  
Net cash used in investing activities (440) [1] (15,335) [1] (41,741) [1] (56,183) (22,851)  
Loan settlement       3,385  
Net Cash provided by financing activities 8,059 [1] 16,832 [1] 65,477 [1] 236,102 41,925  
Net change in cash and cash equivalents       171,008 14,133  
Cash, cash equivalents, and restricted cash at end of period       185,574 14,566 $ 433
As Previously Reported [Member]            
Restated Audited Consolidated Statement of Cash Flows [Line Items]            
Consolidated net loss (3,548) [1] (8,126) [1] (12,238) [1] (15,754) (8,140)  
Depreciation and amortization 513 730 1,635 2,319 81  
Adjustment Fair Value Of Warrants        
Gain on standby equity purchase agreement          
Issuance costs related to warrants        
Issuance costs related to SEPA          
Amortization of notes payable discount          
Inventory (248) (343) (334) (232) (326)  
Accounts receivable   321 [1]   (421)    
Non-operating losses       (108)    
Deferred income taxes       518  
Change in operating lease liabilities       225    
Accrued expenses and other payable   (91) [1]     38  
Net cash used in operating activities (3,578) [1] (8,076) [1] (11,197) [1] (9,043) (5,060)  
Purchase of PPE (78) (116) (4,509) (5,009) (725)  
Purchase of intangible assets     (100) [1] (591) (5,470)  
Purchase of short-term investments       (41,975)    
Net cash used in investing activities (380) [1] (15,130) [1] (41,532) [1] (47,996) (22,731)  
Loan settlement         3,383  
Net Cash provided by financing activities 9,219 [1] 19,766 [1] 71,056 [1]   41,923  
Net change in cash and cash equivalents       179,063 14,132  
Cash, cash equivalents, and restricted cash at end of period       193,629    
Restatement Adjustment [Member]            
Restated Audited Consolidated Statement of Cash Flows [Line Items]            
Consolidated net loss (26,017) [1] (22,011) [1] (19,591) [1] (33,428) 6,772  
Depreciation and amortization (232) (225) (694) (932) 17  
Adjustment Fair Value Of Warrants       34,172 (5,185)  
Gain on standby equity purchase agreement         (2,402)  
Issuance costs related to warrants       189 371  
Issuance costs related to SEPA         319  
Amortization of notes payable discount         120  
Inventory 60 270 331 136 119  
Accounts receivable   (94) [1]   (1)    
Non-operating losses       108    
Deferred income taxes       (108) 108  
Change in operating lease liabilities       (4)    
Accrued expenses and other payable   3 [1]     (120)  
Net cash used in operating activities 1,220 [1] 3,139 [1] 5,788 [1] 132 119  
Purchase of PPE (60) (270) (330) (135) (119)  
Purchase of intangible assets     16 [1] 1 (1)  
Purchase of short-term investments       (8,053)    
Net cash used in investing activities (60) [1] (205) [1] (209) [1] (8,187) (120)  
Loan settlement         2  
Net Cash provided by financing activities $ (1,160) [1] $ (2,934) [1] $ (5,579) [1]   2  
Net change in cash and cash equivalents       (8,055) $ 1  
Cash, cash equivalents, and restricted cash at end of period       $ (8,055)    
[1] Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.